Cancer Research

Article	Citations
Abstract P1-13-04: Evaluation of the impact Vitamin D and Calcium supplementation on bone mineral density in breast cancer patients using or not taking Aromatase Inhibitors: 5-year follow-up	363
Abstract P4-12-09: Implications of protocol modifications and treatment delays for breast cancer patient experiences during Covid-19	174
Abstract P2-12-23: Changes in 18F-FDG-PET uptake after the first course of DTX reflect response to preoperative chemotherapy and prognosis in breast cancer	167
Abstract OT1-05-01: Glycoprotein 88 (GP-88) serum levels as a marker of response to therapy in patients with metastatic breast cancer	155
Abstract 1013: Mechanistic role of nelfinavir as drug-repurposing strategy against high-grade serous ovarian cancer	152
Abstract P3-19-16: Impact of targeted intraoperative (TARGIT-IORT) tumor bed boost during breast conserving surgery for early breast cancer on breast cancer associated and non-breast cancer associated	152
Abstract 1151: Targeting castration-resistant prostate cancer using mesenchymal stem cell exosomes for therapeutic microRNA let-7c delivery	140
Abstract 1001: Treatment of RB1-intact cancers with CDK4/6 inhibitor combination therapy	139
Abstract 2916: Characterization of a mouse model of leptomeningeal melanocytic disease	134
Abstract 2884: Wnt11 dictates the patterns and latency of pulmonary micrometastatic disease in pancreatic cancer	130
Abstract 2575: Intermittent calorie restriction reverses the adverse effects of obesity and advanced age on tumor growth in a mouse model of breast cancer	126
Abstract 1221: The landscape of 2,706 RET alterations from 89,754 adult patients with cancer: Clinical implications	124
Abstract 1235: Selective androgen receptor degraders for the treatment of androgen receptor-positive, triple-negative breast cancer	123
Abstract 2650: Angiogenic inhibitors reduce mycosis fungoides cell survival and enhance cell death	121
Abstract 2945: Novel engineered B-NDG B2M/KO mice plus and steroid treated B-NDG Mice shows delayed GvHD response when engrafted with hPBMC	118
Abstract 2481: Time-resolved transcriptome analysis of murine TH-MYCN driven neuroblastoma identifies MEIS2 as early initiating factor and novel core gene regulatory circuitry constituent	117
Abstract 2969: Impact of baseline culture condition on the growth and treatment response of mouse derived cancer organoids	114
Abstract 2648: A dual functional agent inhibits the angiogenesis and DNA synthesis resulting in the growth suppression of consensus molecular subtypes 1 and 4 in colorectal cancer xenografts	113
Abstract 2735: Clinical significance of CD4+CD7−helper T-cells and tumoral CD7 expression in colorectal cancer	109
Abstract 2957: A novel circulating tumor DNA (ctDNA) assay enables monitoring of disease progression and treatment response in disseminated preclinical hematologic cancer models	106
Abstract 2807: Variations in glycolytic activity of HCC subtypes as monitored by in vivo h 13C MRI	104
Abstract 2951: Anti-GCGR in vivo efficacy evaluated in a novel humanized B-hGCGR mouse model	103
Abstract 2574: Collagen density and obesity promote mammary gland inflammation	101
Abstract 317: Berberine-mediated reprogramming of the inflammatory environment in anaplastic thyroid cancer	101
Abstract 3192: PD-L1 is an independent prognostic marker in Middle Eastern PTC and its expression is upregulated by BRAFV600E mutation	100

Abstract 525: Novel DARPin multi-specific T-cell engager with an improved therapeutic window to overcome dose limiting toxicities in AML therapies	100
Abstract 322: Protein expression shift and potential diagnostic markers through proteomics profiling of A549 lung cancer cells	97
Abstract 324: Unbiased proteomic and phosphoproteomic analysis identifies response signatures and novel susceptibilities after combined MEK and mTOR inhibition in BRAFV600E mutant glioma	97
Abstract 375: High tumor mutation burden predicts unfavorable clinical outcome in EGFR-mutated lung adenocarcinoma treated with targeted therapy	96
Abstract 433: Clinical validation of a Dickkopf-1 (DKK1) chromogenic in-situ hybridization (CISH) assay for manual and image-analysis assisted pathologist interpretation	95
Abstract 1545: Development of FGFR4-targeted chimeric antigen receptors (CARs) for the treatment of rhabdomyosarcoma	89
Abstract 184: The utility of deep metric learning for breast cancer identification on mammographic images	89
Abstract 1406: FOXC1 induces cisplatin resistance through enhancer activation in bladder cancer	87
Abstract 1366: Integrated population modeling of loncastuximab tesirine (Lonca) exposure in B-cell non-Hodgkin lymphoma (B-NHL)	86
Abstract 1381: Impact of PI3K/mTOR inhibitors on the development of taxane resistance	85
Abstract 1305: Classification of cell morphology using machine learning and label-free live-cell imaging	85
Abstract 1327: Role of intra-tumoral bacteria in EGFR-tyrosine kinase inhibitor resistance	83
Abstract 1790: BO-112 as a modifier of the tumor microenvironment for liver metastases	82
Abstract 1430: In vivo PoC study and design for Phase I clinical study of SJP1604, a nucleolin-targeted therapeutic agent to treat entire population of relapsed/refractory acute myeloid leukemi	79
Abstract 1479: Pan-cancer efficacy of BRAF and/or MEK inhibitors in BRAF V600-mutant multiple non-melanoma cancers: A clinico-genomic study	78
Abstract 133: Skeletal muscle transcriptome profiling of human pancreatic cancer cachexia: single largest study in cachexia	78
Abstract 1896: The genomic features of Chinese cancer patients harboring HLA LOH	77
Abstract 1629: IO-202, a first-in-class LILRB4 antagonist antibody, activates dendritic cells and inhibits solid tumor growth in preclinical studies	77
Abstract 1634: Siglec-15 knockout inhibits tumor growth in mouse model	77
Abstract 1513: A case study investigation into the role of CD4+ tumor-infiltrating lymphocytes in a metastatic melanoma patient with a complete response to adoptive cell therapy	76
Abstract 1980: Non-canonical regulation and function of anti-apoptotic protein c-FLIP	76
Abstract 1324: Evaluation of KIF14 in a chemotherapeutic resistant breast cancer cell line	76
Abstract 1587: Generation and characterization of novel bispecific molecules combining single-chain-CD40L with anti-CEA, anti-CD95L or anti-PD-L1 targeting moieties	74
Abstract 1362: Exposure-response (E-R) analysis of efficacy for avelumab as first-line maintenance therapy for urothelial carcinoma in the JAVELIN Bladder 100 study	72
Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative l	71
Abstract P5-08-02: MORAb-202, an antibody-drug-conjugate (ADC) targeting folate receptor alpha (FRα), exhibits durable anti-tumor efficacy in PDx models of TNBC	69
Abstract P3-20-09: Surgery vs radiation therapy as the first stage treatment in patients with locally advanced breast cancer with incomplete clinical response	69
Abstract CT144: Development of GMI-1359, a novel agent targeting tumor-microenvironment cross-talk in bone metastatic cancer	68
Abstract P3-12-20: Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+ early stage breast cancer	68
Abstract P4-01-16: Overcome chemoresistance of triple-negative breast cancer by inhibiting the RNA-binding protein HuR	67
Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy	67
Abstract PD3-03: EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression	66
Abstract LB071: Tuning the tumor myeloid microenvironment (TME) by targeting TREM2+ tumor-associated macrophages to overcome resistance to immune checkpoint inhibitors	66
Abstract OT2-21-01: A randomized, multicenter pragmatic trial comparing bone pain from a single dose of pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adj	66
Abstract P4-11-16: Feasibility and patient satisfaction with a smartphone application to improve medication adherence among patients with breast cancer	65
Abstract 2126: Therapeutic potential of CPI-0209	65
Abstract P3-18-14: Assessment of quality of life and objective cosmetic outcome of breast conserving surgery with or without latissimus dorsi mini-flap in breast cancer	64
Abstract P4-05-09: Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience	64
Abstract 3175: FAT1 and the immunosuppressive milieu in glioblastoma tumors	64
Abstract P4-10-10: Effectiveness and feasibility of exercise-oncology programs in breast cancer patients using new technologies adapted to the COVID 19 new normality	64
Abstract P1-08-09: High mid-treatment RNA disruption in patients with HER2-negative breast cancer predicts survival benefit after neoadjuvant chemotherapy	63
Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS	62
Abstract P4-11-05: How to stay sexually active and sexually well-functioning after breast cancer - Reporting from the SWEET study	62
Abstract P5-14-10: Examining inequities associated with incarceration among patients with breast cancer	60
Abstract NG14: Reduction in mitochondrial priming drives resistance to targeted therapy in acute myeloid leukemia	60
Abstract ES8-2: Can radiation replace ALND after positive SLNB?	60
Abstract P1-08-07: Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with	60
Abstract P1-06-01: Insights from rapid autopsy shed light on mechanisms of cancer dissemination in metastatic breast cancer	60
Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast	58
Abstract 442: Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189	58

Abstract PD4-03: Characterization of HER2 amplification in the cerebrospinal fluid of patients with Leptomeningeal Disease in stage IV patients with breast cancer	58
Abstract 864: Changes over time in real-world next-generation sequencing (NGS) test use in patients (pts) with advanced non-small cell lung cancer (aNSCLC)	58
Abstract 867: Incidence of molecular alterations in KRAS and other known cancer genes in patients with pancreatic cancer assessed with a commercial genomic profiling panel compared to TCGA results	57
Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors	57
Abstract P5-13-17: PD-L1 expression in breast to brain metastases	57
Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-	56
Abstract P2-15-01: Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer	56
Abstract P4-12-14: Assessing patients perceptions on hormone therapy for breast cancer: Insights from a Brazilian patient group	56
Abstract 1220: Selective and broad anti-tumor activity of AKR1C3-activated prodrug AST-3424/OBI-3424	55
Abstract 715: Flow cytometry analysis of immune response to COVID-19 vaccine candidates using an in vitro stimulation model	54
Abstract 407: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response	54
Abstract 2048: Property analysis of chromosomal instability-adapted cells using multi-omics approaches	54
Abstract 494: Novel human B7-H3 knock-in mice demonstrate efficacy of anti-B7-H3 immunotherapy in vivo	53
Abstract 532: Association of pCR and the 8-gene signature: NRG Oncology/NSABP B-41	53
Abstract 3193: Development and functional characterization of NC762, a novel therapeutic antibody targeting B7-H4, for the treatment of malignancies	53
Abstract 2030: Oncological relevance of protein hydroxylase inhibitors (PHI): results of testing an emerging concept with an orally active pioneer medicine that blocks the hydroxylations of proline an	53
Abstract 845: Association of nut consumption with risk of total and specific cancers: Evidence from three large prospective cohort studies	52
Abstract 2338: The GLS1 inhibitor IPN60090 enhances antitumor immune response through metabolic reprogramming of T cells and impacts on the tumor microenvironment	52
Abstract 3165: Stroma-immune landscape in lymphoma: new mechanisms of immunosuppression and therapeutic targeting	52
Abstract 2333: EMT programs ovarian cancer cells to survive the adipocyte-rich microenvironment	51
Abstract 893: Batch effects in tumor biomarker studies using tissue microarrays: Extent, impact, and remediation	51
Abstract 856: Proteomic analysis of serum in workers exposed to diesel engine exhaust	51
Abstract 2433: Core regulatory circuits of clear cell ovarian and kidney cancers	51
Abstract 2592: Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer	50
Abstract 902: Contributions of cancer treatment, comorbidities and obesity to aging-related diseases risks in B-cell non-Hodgkin's lymphoma survivors	50
Abstract 810: Enrichment and screening of LFS patients by analyzing TP53 germline mutations of a Chinese cancer cohort	50
Abstract 2535: Leukemic Cell Proteomic Profiling in Pediatric AML	50
Abstract 2331: Metabolic evasion of mCRPC immunotherapy by ACOD1 production of itaconate	50
Abstract 2457: NANOG bindsPRC2 to reprogram metabolismandpromotelabel-retaining populationin experimental mouse and clinical carcinoma	50
Abstract LB179: Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastroint	49
Abstract 986: Induction of lytic cycle of Epstein-Barr virus by a novel organic compound through activation of the c-Jun N-terminal kinase pathway	49
Abstract 740: A robust rapid mRNA based test to profile simultaneously ER, AR, PI3K and MAPK functional signaling pathway activity for precision oncology	49
Abstract NG09: Bioengineered tissue mimetic hydrogels to study brain tumor biology and screen therapeutics	49
Abstract PO-119: DFMO mediated improvement in survival of an orthotopic model of pancreatic cancer is associated with modulating immune suppression in the tumor microenvironment	49
Abstract 2260: Evaluating a rare t(X;14)(q28;q32) translocation reveals MTCP1 as a driving factor in chronic lymphocytic leukemia	49
Abstract LB188: RNA-seq and chIP-seq profiling identifies genes and pathways dysregulated by hey1-ncoa2 fusion and shed a light on mesenchymal chondrosarcoma tumorigenesis	49
Abstract 905: Investigating the effects of aerobic exercise on preclinical breast cancer outcomes	49
Abstract 1342: Development and preclinical evaluation of unique first-in-class small molecule inhibitors of the anti-apoptotic protein FLIP	48
Abstract LB129: Stratification of radiotherapy and fluoropyrimidine-based chemotherapy from multi-omic profiling in rectal cancer biopsies	48
Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies	48
Abstract 1472: Novel EGFR WT sparing, HER2 selective inhibitors for the treatment of HER2 exon 20 insertion driven tumors address a clear unmet medical need	48
Abstract LB072: SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus	48
SMARCA4 Inhibits Breast Cancer Progression and Metastasis through RHOA Suppression	48
A Reflection on How Carcinoma-Associated Fibroblasts Were Recognized as Active Participants of Epithelial Tumorigenesis	46
Editor's Note: p38 Mitogen-Activated Protein Kinase-Driven MAPKAPK2 Regulates Invasion of Bladder Cancer by Modulation of MMP-2 and MMP-9 Activity	46
Hyperactive Dendritc Cells Redirect Aged Antitumor Immunity	46
Correction: Mitochondrial DNA Repair through OGG1 Activity Attenuates Breast Cancer Progression and Metastasis	46
Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma	46
A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants	45
Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer	45
Abstract P1-18-17: Phase I study of cfi-402257, an oral ttk inhibitor, in patients with advanced solid tumors with breast cancer expansion cohorts	45
Stayin' Alive: Targeting Chromatin Regulators of Clonal Hematopoiesis Promotes CD8 T-cell Stemness	45
Abstract 207: The cBioPortal for Cancer Genomics	45
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors	44
Abstract CT023: PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM)	44
Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C–MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies	44
Abstract 3107: HSB-1216, A Novel Agent for the Treatment of Chemotherapy-Resistant ES-SCLC	44
The Warburg Effect Revisited through Blood and Electron Flow	44
Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T Cell Immunotherapy	43
Abstract P5-01-03: Mouse-intraductal (MIND): An in vivo model for studying the underlying mechanisms of DCIS malignancy	43
Abstract 528: MDSC suppress the T cell repertoire and contribute to a pathologic cytokine milieu in cancer patients	43
Abstract PD15-02: HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer	43
Abstract 2449: FGFR4 inhibitor BLU9931 induces cellular senescence in pancreatic ductal adenocarcinoma cell lines promoting sensitivity to senolytic therapy	43
Abstract 2391: Computation of a user-friendly composite score from three prostate cancer biomarkers	43
Abstract 3054: Synergistic activity of DNA damage response kinase inhibitors in combination with the targeted alpha therapy radium-223 dichloride for metastatic castration-resistant prostate cancer	42
Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL	42
NCI Imaging Data Commons	41
NCI Cancer Research Data Commons: Core Standards and Services	41
Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy–Refractory Cancer Growth	41
Leveraging Tissue-Specific Enhancer–Target Gene Regulatory Networks Identifies Enhancer Somatic Mutations That Functionally Impact Lung Cancer	41
FOXP4 Is a Direct YAP1 Target That Promotes Gastric Cancer Stemness and Drives Metastasis	41
Abstract SY17-03: Tumor-associated antigen MUC1 vaccine for colon cancer prevention	41
Abstract GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast can	40
Abstract 588: Mesenchymal markers: The new avenue for circulating tumor cells detection	40
Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors	40
Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity	40
The Central Role of mTORC1 in Amino Acid Sensing	40
PROX1: a key regulator of hepatocyte identity and tumorigenesis	40
Abstract 1843: Therapeutic implication of pH/hypoxic responsive nanoencapsulated tunicamycin on pancreatic cancer by targeting K-RasG12D	39
Abstract 3005: Discovery of a potential therapeutic mechanism for selected tumors via targeting PI3K and DDR pathways simultaneously with a novel orally available small molecule	39

Abstract 2232: BGB-R046, an IL-15 pro-drug demonstrates robust pharmacodynamic effects and immune activation within tumor microenvironment in a mouse syngeneic model	39
Structure, Dynamics, and Impact of Replication Stress–Induced Structural Variants in Hepatocellular Carcinoma	39
Abstract 4217: Effect of HDAC3 targeting on endometrial cancer progression and therapeutic potential	39
Abstract 3510: A 2+1 format MUC16 targeting T cell engager induces MUC16-dependent T cell activity and superior anti-tumor efficacy	39
Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer	39
Abstract 3793: Advancing GPC3-positive solid tumor therapy with AZD9793, a novel CD8-guided T cell engager with potent pre-clinical efficacy and superior therapeutic index over GPC3 x CD3 formats	39
Abstract 7092: The change in Asian American/Native American/Pacific Islander demographics in interventional clinical trials in Hawai'i	38
Abstract 5333: CDK4/6 inhibitors in patients with bone-only metastatic breast cancer, the role of immune microenvironment	38
Abstract 2028: Development of a miRNA-based prognostic signature for clear cell renal cell carcinoma	38
Abstract 3216: A dual-acting chimeric peptide inhibits tumor growth by inhibiting PD-L1 and inducing immunogenic cell death	38
Abstract 1783: Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors	38
Abstract 2696: Targeting SLC7A11 creates a favorable immune microenvironment in colorectal cancer	38
Abstract 1701: Investigating trastuzumab-deruxtecan (DS-8201) resistance mechanisms using clinically relevant PDX models and combination strategies with anti-PD-1 antibody	38
Abstract 6065: Preclinical evaluation of LM-168: A next-generation anti-CTLA4 antibody with promising efficacy and reduced toxicity	38
Abstract 242: Differential activation of TAM receptors by Gas6 and protein S	38
Abstract 6302: A CellProfiler pipeline for RNAscope analyzing multiple markers across adjacent tissue sections spatially	37
Abstract 3842: ZNF217 promotes breast tumor progression by facilitating angiogenesis	37
Abstract 6114: Engineering novel synNotch CAR T cells to precisely and effectively target medulloblastoma	37
Abstract 6762: Baseline multiomics and chemotherapy efficacy in preclinical trials using patient-derived xenograft models of cholangiocarcinoma can reveal distinct signatures of chemotherapy response	37
Abstract 6826: PRMT5 inhibition is a promising therapeutic strategy for high-risk neuroblastoma	37
Abstract 2513: Factors influencing participant attrition in Phase 0 hybrid clinical trials for patients with high-grade glioma	37
Abstract 6337: A novel PMS2 mutant Lynch syndrome mouse model for cancer prevention studies	37
Abstract 5379: NNMT loss drives prostate cancer progression through epigenetic and metabolic reprogramming	37
Abstract 4862: Targeting fli1 improves antitumor response of CD8 T cells by promoting their activation and limiting exhaustion	36
Abstract 5671: Development of HTS enzymatic assays for VPS4A and related ATPases	36
Abstract 5708: Investigating the role of SMYD3 in medulloblastoma progression and treatment response: Implications for targeted therapy	36
Abstract 7189: EED inhibitor APG-5918 renders vulnerability to immunotherapy by rewiring sphingolipid metabolism via nSMase2-ceramide pathway in pancreatic cancer	36
Abstract 6991: Targeting NONO as a therapeutic strategy for metastatic castration-resistant prostate cancer (CRPC)	36
Abstract 7306: Selective and novel ALDH1 inhibitor enhances immune checkpoint blockade therapy in preclinical models of MSS colorectal cancer	36
Abstract 6310: Bridging spatial proteomics and classical histopathology: advanced spatial analysis through H&E-enhanced multiplexed immunoprofiling	36
Abstract 5649: Potentiation of AKR1C3- and P53-dependent AST-3424 activity via PUMA-mediated degradation of Rad51	35
Abstract 6996: Integrating high-throughput screening with ligand-based pharmacophore modeling and virtual screening strategies to optimize exonuclease 1 inhibitor design	35
Abstract 7449: Evaluating the effectiveness of machine learning models using polygenic risk scores and clinical factors for breast cancer risk stratification	35
Abstract 4002: Development of an organoid coculture model to investigate tumor immune interactions and therapeutic strategies in prostate cancer	35
Abstract 6922: MDM2 inhibitor alrizomadlin induces ferroptosis through p53 dependent and independent pathways in TP53 wildtype NSCLC	34
Abstract 7008: Development of a potent SOS1 degrader exhibiting superior combination effects with anti-cancer drugs in various tumor models	34
Abstract 6880: Rinatabart sesutecan (PRO1184) in combination with standard-of-care therapy exerted potentiated antitumor activity in preclinical cancer models	34
Abstract 6755: Discovery of the synergistic dual-payload antibody-drug conjugate (CTPH-02) by combination of MMAE and novel payloads	34
Abstract 6939: MAPKAP kinase 2 regulates inflammatory responses in glioblastoma	34
Abstract 4867: Enhancing TCR-T with a Fas-based switch receptor boosts T cell engraftment, persistence, and anti-tumor activity in models of hard-to-treat PRAME solid tumor indications	33
Abstract 7229: Humanized mouse models of γδ T engraftment for the testing of cell based anti-cancer therapeutics	33
Abstract 5761: Unbiased phosphoproteomic and metabolic profiling in WT and KRAS mutant colorectal cancer cells reveals molecular interplay between protein regulation and metabolic rewiring	33
Abstract 3163: Discovery of highly selective ligands for the Bcl-2 family of proteins using DNA-encoded chemical libraries	33
Abstract 6400: Preclinical efficacy of combinatorial B7-H3 CAR T cell and ONC206 treatment in DIPG/DMG	33
Abstract 4653: Platelet to lymphocyte ratio and platelet count: new frontiers as prognostic factors in metastatic colorectal cancer patients receiving anti-angiogenic drugs	33
Abstract 1718: Role of IKKε in resistance to second-generation hormone therapy in prostate cancer	33
Abstract 3514: AZD6621: Improving the therapeutic index for prostate cancer T cell engagers with a next-generation CD8-guided format	33
Abstract 4192: Preclinical characterization of LAE122, a novel, potent and selective WRN inhibitor for the treatment of MSI-H tumors	33
Abstract 2954: CS5007: A novel EGFR and HER3 dual-targeted antibody-drug conjugate (ADC) with potent antitumor activity in preclinical studies	33
Abstract 3603: Racial and ethnic disparities in colorectal cancer-specific mortality: The Multiethnic Cohort	32
Abstract 5690: Targeting MET activation in CDH1 deficient diffuse gastric cancer with peritoneal metastases	32
Abstract 1762: Preclinical and clinical studies of PEP07, a novel brain penetrating oral Chk1 inhibitor, on AML and MCL treatments	32
Abstract 3261: Plasma whole-genome sequencing to monitor pancreatic cancer	32
Abstract 3849: Pygo2 deletion stimulates tertiary lymphoid structure formation and forms the cornerstone for a quadruple combination immunotherapy of prostate cancer	32
Abstract 3224: An indirect Meta-analysis of efficacy and safety of PD-1 inhibitors versus PD-L1 inhibitors as preoperative therapy in patients with solid tumors	32
Abstract 4772: AI-guided engineering and preclinical development of biparatopic anti-DLL3 antibody-drug conjugates (ADCs)	32
Abstract 3887: Clonal expansion in the bile duct associated with primary sclerosing cholangitis	32
Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma	32
Abstract 5778: Intra-operative visualization of metastatic sentinel lymph nodes in early breast cancer: An approach to omission of axillary surgery	32
Abstract 2405: NGS-based molecular profiling reveals remarkable anticancer synergy of EZH1/2 dual inhibitor HM97662 with standard-of-care therapy on small cell lung cancer	31
Abstract 3824: Investigating the role of allelic imbalance in pancreatic cancer aggressiveness, survival, and therapeutic resistance	31
Abstract 5753: Multi-omic analysis links neighborhood disadvantage to elevated stress hormones and tumorigenic markers in ER+ breast cancer patient plasma and tumor samples	31
Abstract 4914: Association of HOXB13 G84E with prostate cancer among 592, 158 men	31
Abstract 2670: Understanding cell-of-origin influence on cancer-associated fibroblasts in lung adenocarcinoma	31
Abstract 4831: DNA methylation of immune synapse genes drives tumor immune evasion	31
Abstract 3159: The 5-base genome, a simultaneous detection of genomic and methylation signatures using a concise, integrated multiomic library prep	31
Abstract 3810: Targeting the ADAR1/PKR pathway in TP53-mutant acute myeloid leukemia	31
Abstract 4014: Prognostic evaluation of breast cancer long-term survival outcomes: contributions from a Brazilian hospital-based cohort	31
Abstract 1504: Harnessing the power of mangifera indica: Activation of Nrf2 by leaf-derived oxylipins	31
Abstract 5755: Expansion of the known functional diversity of human T cells achieved due to the unprecedented resolution of intracellular proteins by mass cytometry (CyTOF)	31
Abstract 5774: Enhancing urothelial carcinoma treatment with nectin-4-PET: A predictor of enfortumab vedotin efficacy	31
Abstract 5544: Identification, isolation and molecular characterization of drug-resistant sub-populations of pancreatic cancer cells	31
Abstract 1772: A novel small molecule inhibitor, HO-4200, modulates macrophage polarization and suppresses MDSCs to enhance antitumor immune responses in ovarian cancer	31
Abstract 1632: EGFR-TKIs facilitate cuproptosis via regulating SLC31A1 in cancer cells	30
Abstract 5017: A multimodal deep learning approach to predict survival in never smoking lung cancer patients	30
Abstract 2250: UCHL1 hijacks tolerogenic DC maturation and promotes mregDC-Treg crosstalk to nullify anti-PD-L1 therapy	30
Abstract 3848: Smoking promotes angiogenesis and epithelial to mesenchymal transition in breast cancer	30
Abstract 5956: Glioblastoma in Appalachia: A retrospective analysis	30
Abstract 6327: Prevention of glioblastoma cell growth by Vialinin A	30
Abstract 5750: Discovery of GSK4418959 (IDE275): A novel, non-covalent, reversible Werner Helicase inhibitor and a new potential therapeutic for the treatment of MSI-H cancers	30
Abstract 5131: Dysregulated cholesterol metabolism facilitates epithelial-to-mesenchymal transition and tumor progression in colorectal cancer	30
Abstract 4224: The pharmacological intervention of protein arginine methyltransferase 1 (PRMT1) leads to metastatic castration-resistant prostate cancer (mCRPC) repression through unique and significa	30
Abstract 2933: IDP-001 is a potent bispecific ADC with in vivo activity against mouse xenograft tumor models expressing EGFR and CDCP1	30
Abstract 6297: Mapping cellular interactions from spatially resolved transcriptomics data	30
Abstract 7131: Integrative single-cell transcriptomic and epigenomic immune profiling reveals parallel insights into cancer research	29
Abstract 6681: Identification of a panel of four exosomal microRNAs driving T cell dysfunction in the tumor-immune microenvironment of high-grade serous ovarian cancer	29
Abstract 5887: NALCN promoter methylation as a biomarker for metastatic risk in a cohort of non-small cell lung cancer patients	29
Abstract 7211: Proteolysis targeting chimeras (PROTACs) of oncogenic RET protein	29
Polypharmacologic Reprogramming of Tumor-Associated Macrophages toward an Inflammatory Phenotype	29
Abstract 7326: ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases	29
Abstract 6271: Interactions between CD8+ T cells and tumor cells decode tumor heterogeneity and provide treatment recommendations for colorectal cancer	29
Abstract 4454: Cancer cell permeability induced by tumor treating fields (TTFields) improves chemotherapy uptake and requires cells to transverse through the G2/M phase under TTFields application	29
Abstract 3434: Evaluation of TCR-engineered T cells specific for KRAS G12V mutant peptide presented by HLA-A*02:01	29
Abstract 4575: mRNA expression in paired saliva and blood samples from different cancer indices	29
Abstract 7035: Targeting Ewing sarcoma with a novel RBM39 degrader: DNA damage repair pathway effects	29